Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMVJW0S)

Drug Name
AT-406 Drug Info
Synonyms
1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143
Cross-matching ID
PubChem CID
25022340
ChEBI ID
CHEMBL2158051
CAS Number
CAS 1071992-99-8
TTD Drug ID
D03MXK

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
NF-kappa B signaling pathway 2.32 0.00e+0 90/104 (86.54%) CXCL8;RELB;BIRC3;...
IL-17 signaling pathway 2.29 0.00e+0 84/94 (89.36%) CXCL8;LCN2;MMP9;...
Rheumatoid arthritis 2.27 0.00e+0 78/93 (83.87%) CXCL8;CXCL1;CCL20;...
Influenza A 2.21 0.00e+0 156/172 (90.7%) CXCL8;MX1;IL6;...
Legionellosis 2.17 0.00e+0 51/57 (89.47%) CXCL8;CXCL1;IL6;...
Herpes simplex virus 1 infection 2.15 0.00e+0 165/498 (33.13%) BIRC3;IL6;CCL2;...
Epstein-Barr virus infection 2.13 1.74e-3 189/202 (93.56%) RELB;RUNX3;TNFAIP3;...
NOD-like receptor signaling pathway 2.12 1.52e-3 145/181 (80.11%) CXCL8;BIRC3;CXCL1;...
TNF signaling pathway 2.06 2.71e-3 103/112 (91.96%) BIRC3;MMP9;CXCL1;...
Measles 2.05 2.44e-3 133/139 (95.68%) MX1;TNFAIP3;IL6;...
Malaria 2.05 2.21e-3 44/50 (88%) CXCL8;TGFB2;IL6;...
Hepatitis B 1.98 2.03e-3 151/162 (93.21%) CXCL8;MMP9;TGFB2;...
Fc gamma R-mediated phagocytosis 1.96 2.81e-3 79/97 (81.44%) MARCKS;PLPP2;HCK;...
Small cell lung cancer 1.94 3.48e-3 90/92 (97.83%) BIRC3;LAMB1;TRAF3;...
Leishmaniasis 1.93 4.06e-3 67/77 (87.01%) TGFB2;STAT1;NFKBIA;...
Amoebiasis 1.92 3.81e-3 99/102 (97.06%) CXCL8;CXCL1;ACTN1;...
Hepatitis C 1.87 6.45e-3 139/157 (88.54%) MX1;IFIT1;STAT1;...
Cytokine-cytokine receptor interaction 1.86 6.76e-3 246/295 (83.39%) CXCL8;CXCL1;CXCL13;...
Chemokine signaling pathway 1.86 6.41e-3 163/192 (84.9%) CXCL8;CXCL1;CXCL13;...
Viral protein interaction with cytokine and cytokine re... 1.85 6.09e-3 84/100 (84%) CXCL8;CXCL1;CXCL13;...
Tuberculosis 1.84 6.96e-3 159/180 (88.33%) TGFB2;IL6;STAT1;...
Toll-like receptor signaling pathway 1.83 7.19e-3 94/104 (90.38%) CXCL8;IL6;STAT1;...
Epithelial cell signaling in Helicobacter pylori infect... 1.81 6.88e-3 62/70 (88.57%) CXCL8;CXCL1;NFKBIA;...
Human papillomavirus infection 1.81 6.60e-3 284/331 (85.8%) MX1;COL9A3;ISG15;...
Vibrio cholerae infection 1.80 6.82e-3 44/50 (88%) GNAS;SLC12A2;KDELR3;...
Osteoclast differentiation 1.78 8.43e-3 117/127 (92.13%) RELB;TGFB2;STAT1;...
AGE-RAGE signaling pathway in diabetic complications 1.78 8.12e-3 97/100 (97%) CXCL8;TGFB2;IL6;...
Yersinia infection 1.77 8.26e-3 120/137 (87.59%) CXCL8;IL6;CCL2;...
Human T-cell leukemia virus 1 infection 1.77 7.98e-3 197/219 (89.95%) RELB;TGFB2;MMP7;...
RIG-I-like receptor signaling pathway 1.76 8.49e-3 64/70 (91.43%) CXCL8;ISG15;TRAF3;...
Drug metabolism -1.64 4.80e-2 78/151 (51.66%) CYP3A5;ADH6;GSTM4;...
Huntington disease -1.65 4.94e-2 233/306 (76.14%) PSMB4;PSMD14;PSMD11;...
Tyrosine metabolism -1.65 4.82e-2 30/36 (83.33%) ADH6;TYR;ALDH3A1;...
Retinol metabolism -1.70 3.55e-2 41/68 (60.29%) CYP3A5;CYP2C18;ADH6;...
Fatty acid degradation -1.72 2.82e-2 40/43 (93.02%) ACOX1;HADH;ACAT1;...
Peroxisome -1.74 2.67e-2 72/82 (87.8%) ECH1;CAT;PEX10;...
Pentose and glucuronate interconversions -1.76 2.08e-2 17/34 (50%) KL;UGT2B17;DCXR;...
Ribosome -1.78 2.03e-2 113/158 (71.52%) RPL3;RPL27;RPL4;...
Parkinson disease -1.86 7.79e-3 176/249 (70.68%) TRAP1;PSMB4;PSMD14;...
Oxidative phosphorylation -1.91 2.60e-3 93/133 (69.92%) ATP6V1C1;NDUFA6;ATP5F1C;...
Aminoacyl-tRNA biosynthesis -2.00 0.00e+0 15/66 (22.73%) QRSL1;FARSA;GATC;...
Metabolism of xenobiotics by cytochrome P450 -2.11 0.00e+0 49/77 (63.64%) CYP3A5;ADH6;GSTM4;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.04uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.04uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.04uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.04uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.04uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 0.04uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.04uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.04uM - 10uM 24H